FDA approved drug for the treatment of superficial basal cell carcinoma is –
**Core Concept**
The treatment of superficial basal cell carcinoma involves the use of topical agents that inhibit the growth of cancer cells by targeting the cell cycle, particularly the G1 phase. The drugs used in the treatment of superficial basal cell carcinoma are known as chemotherapeutic agents.
**Why the Correct Answer is Right**
The correct answer is a topical agent that works by inhibiting the enzyme dihydrofolate reductase (DHFR), which is essential for the synthesis of tetrahydrofolate, a necessary precursor for DNA synthesis and repair. By inhibiting DHFR, the drug prevents the proliferation of cancer cells. The correct answer has been shown to be effective in treating superficial basal cell carcinoma with minimal side effects.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is a topical corticosteroid, which is used to reduce inflammation and is not effective in treating superficial basal cell carcinoma.
**Option B:** This option is an immunomodulator, which is used to treat certain types of skin conditions, but it is not approved for the treatment of superficial basal cell carcinoma.
**Option C:** This option is a topical agent that works by inhibiting the growth of cancer cells through a different mechanism, but it is not FDA-approved for the treatment of superficial basal cell carcinoma.
**Clinical Pearl / High-Yield Fact**
The treatment of superficial basal cell carcinoma often involves the use of topical agents, which are preferred over systemic therapies due to their localized action and reduced side effects.
**Correct Answer: C. Imiquimod**